Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00977522 · ClinicalTrials.gov registry record · Phase 2
A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 207
- Enrollment target
NCT00977522: Clinical Trial Phase 2 study, sponsored by Pfizer.
NCT00977522 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 207 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00977522, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 207 participants
- Enrollment target
Study Summary
This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
Interventions
- DRUG Placebo
- DRUG PF-03463275
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2009-11 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Why NCT00977522 stopped before completion
NCT00977522 is an interventional study that assigns participants to a tested intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00977522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00977522 about?
NCT00977522 is a clinical study titled "A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia". This study is examining the efficacy of PF-03463275 compared to placebo in treating negative symptoms of schizophrenia when added to ongoing antipsychotic treatment in stable outpatients with schizophrenia.
What is the current status of trial NCT00977522?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 207 participants. The study started on 2009-11. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00977522?
The interventions under investigation include: Placebo (DRUG), PF-03463275 (DRUG).
Who is sponsoring clinical trial NCT00977522?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00977522's enrollment target sits among peer trials
207 297th of 2000 higher than 1,703 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
- NCT05875805 · 207 participants · NA
A Telehealth Advance Care Planning Intervention
- NCT06254950 · 207 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06904274 · 207 participants · Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia